Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
triglyceride
Biotech
Sanofi pens $395M China pact for Arrowhead metabolic med
Sanofi is handing over $130 million upfront for the China rights to Arrowhead’s rare metabolic disease drug currently being considered for approval.
James Waldron
Aug 1, 2025 7:21am
Marea rises toward phase 2b after posting cholesterol data
May 7, 2025 8:25am
Arrowhead posts phase 3 data ahead of market clash with Ionis
Sep 3, 2024 9:27am
Arrowhead RNAi med lowers triglycerides in phase 3
Jun 3, 2024 9:54am
Arrowhead on target in lipid disorder as it pursues Ionis
Apr 8, 2024 9:37am
Acasti abandons omega-3 filing after 2nd phase 3 flop
Sep 1, 2020 9:20am
